Provided by Tiger Trade Technology Pte. Ltd.

4D Molecular Therapeutics

14.14
+0.51003.74%
Volume:183.39K
Turnover:2.53M
Market Cap:781.15M
PE:-5.13
High:14.16
Open:13.65
Low:13.55
Close:13.63
52wk High:16.93
52wk Low:6.47
Shares:55.24M
Float Shares:42.02M
Volume Ratio:0.64
T/O Rate:0.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7580
EPS(LYR):-2.4200
ROE:-43.25%
ROA:-25.09%
PB:1.92
PE(LYR):-5.84

Loading ...

4D Molecular Therapeutics CEO David Kirn Disposes of 12,415 Shares Worth $124,987

Reuters
·
Aug 05

4D Molecular Therapeutics Inc : B. Riley Initiates Coverage with Buy Rating; Target Price $37

THOMSON REUTERS
·
Jul 31

B. Riley Initiates 4D Molecular Therapeutics at Buy With $37 Price Target

MT Newswires Live
·
Jul 31

U.S. Research ROUNDUP-Apple, Amazon, Mastercard

Reuters
·
Jul 31

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Tempus AI, Inc. Class A (TEM) and 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
Jul 21

4D Molecular Therapeutics Posts Strong 4D-150 Trial Results

TIPRANKS
·
Jul 20

4D Molecular Therapeutics Reports Positive 2-year Phase 2b PRISM Data for 4d-150 in Wet AMD

Reuters
·
Jul 20

4D Molecular Therapeutics Price Target Maintained with a $36.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 20

4D Molecular Therapeutics Reports Positive 2-year Phase 2b PRISM Data for 4d-150 in Wet AMD

Reuters
·
Jul 19

4D Molecular Therapeutics - 4d-150 Continues to be Well Tolerated with no New Safety Findings

THOMSON REUTERS
·
Jul 19

4dmt Announces Positive 2-year Data from Prism Phase 2B Clinical Trial in a Broad Wet Amd Population

THOMSON REUTERS
·
Jul 19

Press Release: 4DMT Announces New Employment Inducement Grants

Dow Jones
·
Jul 18

4D Molecular Therapeutics CEO David Kirn Sells USD 739,829 in Common Shares

Reuters
·
Jul 15

4D Molecular Therapeutics Chief Legal Officer Scott Bizily Disposes of 6,566 Common Shares Valued at $91,924

Reuters
·
Jul 03

4D Molecular Therapeutics to Present 2-year PRISM Phase 2b Data for 4d-150 Gene Therapy in Neovascular AMD at ASRS 2026

Reuters
·
Jul 01

Morgan Stanley Keeps Their Hold Rating on 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
Jun 30

4D Molecular Therapeutics Buy Rating Reaffirmed on 4D-150 Pivotal Trial Momentum; Price Target Maintained at $36

TIPRANKS
·
Jun 30

4D Molecular Therapeutics Shares Rise After New Credit Facility

Dow Jones
·
Jun 29

4D Molecular Therapeutics Secures $200 Million Loan Facility

TIPRANKS
·
Jun 29

4D Molecular completes enrollment in 4FRONT-2 trial

TIPRANKS
·
Jun 29